Martin Reck
马丁·雷克
MD, PhD
Head of Thoracic Oncology Department胸部肿瘤科主任
👥Biography 个人简介
Professor Martin Reck is one of Europe's foremost lung cancer specialists. He led the KEYNOTE-024 trial establishing pembrolizumab as first-line therapy for high PD-L1 NSCLC, fundamentally transforming the treatment paradigm for advanced non-small cell lung cancer worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
First-Line Immunotherapy in NSCLC
Led KEYNOTE-024, the pivotal trial demonstrating pembrolizumab monotherapy superiority over chemotherapy in PD-L1 ≥50% NSCLC, establishing a new global standard of care.
Immunotherapy Combinations
Contributed to defining chemo-immunotherapy combinations including KEYNOTE-189 and IMpower150, expanding first-line immunotherapy benefit across broader NSCLC populations.
Biomarker-Driven Treatment Selection
Advanced the clinical application of PD-L1 and TMB as predictive biomarkers, helping stratify patients for optimal first-line immunotherapy regimens.
Representative Works 代表性著作
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine (2016)
KEYNOTE-024: landmark trial establishing pembrolizumab as first-line standard of care for advanced NSCLC with PD-L1 ≥50%, cited worldwide.
Updated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy
Journal of Clinical Oncology (2019)
Long-term follow-up confirming sustained overall survival benefit of pembrolizumab over chemotherapy in high PD-L1 NSCLC patients.
Nivolumab plus Ipilimumab in First-Line NSCLC
New England Journal of Medicine (2019)
CheckMate 227 contributions supporting dual checkpoint blockade as an effective first-line strategy based on TMB and PD-L1 co-selection.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 马丁·雷克 的研究动态
Follow Martin Reck's research updates
留下邮箱，当我们发布与 Martin Reck（LungenClinik Grosshansdorf）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment